Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of intraperitoneal daptomycin in peritoneal dialysis patients with peritonitis
2012-005699-33Phase 2Terminated
- Sponsor
- CHU Caen Normandie
- Start
- Sep 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daptomycin in peritonitis, sponsored by CHU Caen Normandie. Primary endpoint: Pharmacokinetic parameters of intraperitoneal daptomycin. Started Sep 2015; status: terminated.
02
Drugs
daptomycin
03
Conditions
peritonitis
Beyond the preview
Go deeper on 2012-005699-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005699-33.